{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-144204","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.079043+00:00","generated_at":"2026-05-19T00:08:29.754073+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Candel Therapeutics Appoints Charles Schoch as Permanent CFO, Effective June 20, 2025","bullets":["Charles Schoch, interim CFO since Jan 2024, promoted to permanent CFO; base salary increased to $440,000, target bonus 40%.","Granted option to purchase 50,000 shares; 25% vests at one year, then ratably over 36 months.","Schoch previously served as VP Finance and Corporate Controller; led capital raise of ~$86M in Q4 2024.","Press release highlights upcoming BLA submission for CAN-2409 in localized prostate cancer.","No family relationships or arrangements with other parties disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-144204","json":"https://secwatch.observer/filing/0001193125-25-144204.json","markdown":"https://secwatch.observer/filing/0001193125-25-144204.md","text":"https://secwatch.observer/filing/0001193125-25-144204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000119312525144204/0001193125-25-144204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000119312525144204/d915163d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T00:08:29.754073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"095113276c","claim":"Charles Schoch was appointed as Chief Financial Officer at Candel Therapeutics, Inc..","evidence_excerpt":"On June 20, 2025, the board of directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) unanimously appointed Charles Schoch as the Company’s Chief Financial Officer, effective June 20, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312525144204/0001193125-25-144204-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}